With a make-or-break PhIII readout looming, a struggling Concert offloads a 'portfolio' of drugs
A one-time high-flying biotech which once had big plans for its platform tech is jettisoning a “portfolio” of pipeline drugs as it hunkers down for a make-or-break attempt to compete with two pharma giants in what looks to be an intensely competitive alopecia field.
In a brief statement out on Friday, a tiny outfit called Terran Biosciences put out word that it has snapped up a group of CNS drugs from Concert Pharmaceuticals, which axed its mid-stage schizophrenia drug a little more than a year ago after a crushing Phase II failure. There’s no word on which drugs are involved and not a peep about the dollars involved.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.